IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.
How this was made
The 30-second read
Why it matters
Investors are likely to reprice the stock around (1) whether the Q3 ramp to over 300 units is achievable without further margin deterioration, and (2) whether gross margin can recover as start-up costs fall by more than 50% in Q3.
Market read
This is a primary earnings and guidance update with explicit production targets and margin drivers, which can drive near-term repricing versus prior expectations.
What to watch
Lead times for new systems (four to six months) and the domestic replacement opportunity (6,400 older 3860 channels) could shift revenue timing and working-capital needs, affecting near-term expectations.
Background
IRadimed is transitioning from standing-start production to general release of its new 3870 MR IV MRI-compatible infusion pump, with a mix shift toward four-channel quad systems.
Ticker impact
IRadimed reported Q2 2026 results and guided Q3 revenue to $23M to $24.5M and non-GAAP EPS to $0.54 to $0.59.
Near-term volatility likely, with upside if investors focus on backlog build and cost normalization, and downside if gross margin drag or production strain looks worse than expected.
The article provides multiple decision-useful datapoints: GAAP and non-GAAP EPS, gross margin drivers, production targets (130 to 135 units, Q3 over 300), and explicit Q3 and FY guidance ranges.
Market effects
Medical device makers with manufacturing scale-ups may see investor focus on ramp-related gross margin normalization timelines.
Domestic-heavy revenue mix (82% of total) may keep attention on US replacement demand for legacy MRI pump channels.
Limited direct global read-through beyond MRI-compatible infusion pump demand and production execution.
Counterpoint
The margin compression is tied to the first sizable ramp and could persist longer than management’s learning-curve timeline, making guidance quality more fragile than it appears.
Key entities
- companyIRadimed Corporation
Reports Q2 2026 earnings, 3870 pump ramp progress, gross margin drivers, and issues Q3 and full-year guidance.
- executiveRoger Susi
CEO attributed gross margin compression to manufacturing learning curve and discussed ramp and cost normalization expectations.
- executiveJohn Glenn
CFO discussed gross margin decline drivers and tax rate expectations.
